Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01337752 · ClinicalTrials.gov registry record · Phase 2
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01337752 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT01337752, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and dexamethasone, compared to placebo administered with the combination on the time to first Skeletal Related Event (SRE) on study.
Interventions
- DRUG dexamethasone
- DRUG bortezomib
- DRUG BHQ880
- DRUG BHQ880 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01337752
The ClinicalTrials.gov registry entry for NCT01337752 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT01337752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01337752 about?
NCT01337752 is a clinical study titled "Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency". The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and de...
What is the current status of trial NCT01337752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2012-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01337752?
The interventions under investigation include: dexamethasone (DRUG), bortezomib (DRUG), BHQ880 (DRUG), BHQ880 Placebo (DRUG).
Who is sponsoring clinical trial NCT01337752?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.